WARNING: We do not support Internet Explorer. It is not secure and will not work correctly. Please come back using a newer web browser.
CLSI offers standards on quality management and proficiency testing for the molecular diagnostics laboratory, as well as guidelines on the proper collection, transport, preparation, and storage of specimens. Learn about molecular diagnostic methods for identification of infectious diseases as well as oncological applications for molecular testing.
CLSI MM23 covers the current state of molecular diagnostic methods intended for characterization of solid tumors and covers a range of clinical applications, including diagnosis, prognosis, therapeutic response prediction for available drugs and drugs still in clinical trials, monitoring, and presymptomatic and predisposition testing.
Join CLSI for a webinar on the newly published MM26 Cancer Molecular Testing: Principles of Oncology Test Interpretation, Laboratory and Assay Design, and Clinical Consultation. Learn how to build a cancer testing program and how to maintain and improve a cancer genomics laboratory. Our distinguished speakers will also discuss oncology test interpretation, clinical consultation, and new frontiers in testing. A live Q&A will be available for all your questions about CLSI MM26.
CLSI MM26 focuses on strategies for use of effective communication and consultation channels with clinicians in addition to test utilization management to support improved diagnosis, treatment selection, and risk assessment to guide care for patients with cancer.
This guideline provides recommendations for the laboratory development and use of qualitative nucleic acid microarray methods for the diagnosis and monitoring of infectious diseases. It also presents recommendations for validation and verification, quality control, and interpretation of results.
